In AD patients, monotherapy with insulin[14] or with single representatives of other classes of hypoglycemic medications[15, 16] have been shown to not alter the risk of AD[17], but to potentially improve memory performance and slow cognitive decline. The gene discussed is INS; the disease is Alzheimer disease.